(BSX) Boston Scientific - Overview
Stock: Stents, Defibrillators, Pacemakers, Catheters, Endoscopes
| Risk 5d forecast | |
|---|---|
| Volatility | 22.5% |
| Relative Tail Risk | -11.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.10 |
| Alpha | -41.30 |
| Character TTM | |
|---|---|
| Beta | 0.864 |
| Beta Downside | 0.564 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.06% |
| CAGR/Max DD | 0.53 |
EPS (Earnings per Share)
Revenue
Description: BSX Boston Scientific January 27, 2026
Boston Scientific (BSX) designs, manufactures and markets a broad array of interventional medical devices across two primary segments-MedSurg and Cardiovascular. Its MedSurg portfolio spans gastrointestinal, urological and neuromodulation products (e.g., biliary stents, single-use duodenoscopes, holmium laser systems, spinal cord stimulators), while its Cardiovascular line includes coronary and aortic valve therapies, the WATCHMAN FLX left-atrial appendage closure system, and a full suite of implantable cardiac rhythm devices and remote monitoring solutions.
According to the company’s FY 2025 filing (released March 2026), BSX generated $12.5 billion in revenue, up 6 % year-over-year, with an operating margin of 21 % and diluted EPS of $2.30. R&D spending remained steady at roughly 8 % of revenue (~$1.0 billion), supporting a pipeline that recently added a next-generation bio-absorbable vascular scaffold. On the macro side, U.S. healthcare expenditure is projected to grow ~4 % annually through 2028, driven by an aging population and expanding minimally invasive procedures-both trends that historically boost demand for Boston Scientific’s device categories. A potential headwind is the anticipated tightening of Medicare reimbursement for certain cardiac implantable devices, which could modestly pressure margins if not offset by product mix shifts.
For a deeper, data-driven view of how these dynamics translate into valuation metrics, you might find ValueRay’s analyst framework useful as a next step.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 2.89b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.11 > 1.0 |
| NWC/Revenue: 16.71% < 20% (prev 3.11%; Δ 13.60% < -1%) |
| CFO/TA 0.10 > 3% & CFO 4.53b > Net Income 2.89b |
| Net Debt (10.37b) to EBITDA (4.91b): 2.11 < 3 |
| Current Ratio: 1.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.50b) vs 12m ago 0.38% < -2% |
| Gross Margin: 69.01% > 18% (prev 0.61%; Δ 6840 % > 0.5%) |
| Asset Turnover: 48.33% > 50% (prev 42.51%; Δ 5.83% > 0%) |
| Interest Coverage Ratio: 8.33 > 6 (EBITDA TTM 4.91b / Interest Expense TTM 354.0m) |
Altman Z'' 1.67
| A: 0.08 (Total Current Assets 8.79b - Total Current Liabilities 5.44b) / Total Assets 43.67b |
| B: 0.13 (Retained Earnings 5.57b / Total Assets 43.67b) |
| C: 0.07 (EBIT TTM 2.95b / Avg Total Assets 41.53b) |
| D: 0.26 (Book Value of Equity 4.98b / Total Liabilities 19.20b) |
| Altman-Z'' Score: 1.67 = BB |
Beneish M -3.09
| DSRI: 0.95 (Receivables 2.93b/2.56b, Revenue 20.07b/16.75b) |
| GMI: 0.89 (GM 69.01% / 61.44%) |
| AQI: 0.95 (AQ_t 0.70 / AQ_t-1 0.73) |
| SGI: 1.20 (Revenue 20.07b / 16.75b) |
| TATA: -0.04 (NI 2.89b - CFO 4.53b) / TA 43.67b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of BSX shares?
Over the past week, the price has changed by -2.52%, over one month by -19.61%, over three months by -24.14% and over the past year by -28.76%.
Is BSX a buy, sell or hold?
- StrongBuy: 23
- Buy: 8
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BSX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 104.8 | 40.8% |
| Analysts Target Price | 104.8 | 40.8% |
BSX Fundamental Data Overview February 21, 2026
P/E Forward = 21.5517
P/S = 5.594
P/B = 4.7372
P/EG = 0.8282
Revenue TTM = 20.07b USD
EBIT TTM = 2.95b USD
EBITDA TTM = 4.91b USD
Long Term Debt = 11.14b USD (from longTermDebt, last quarter)
Short Term Debt = 389.0m USD (from shortTermDebt, last quarter)
Debt = 12.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.37b USD (from netDebt column, last quarter)
Enterprise Value = 122.75b USD (112.29b + Debt 12.42b - CCE 1.97b)
Interest Coverage Ratio = 8.33 (Ebit TTM 2.95b / Interest Expense TTM 354.0m)
EV/FCF = 33.86x (Enterprise Value 122.75b / FCF TTM 3.62b)
FCF Yield = 2.95% (FCF TTM 3.62b / Enterprise Value 122.75b)
FCF Margin = 18.06% (FCF TTM 3.62b / Revenue TTM 20.07b)
Net Margin = 14.40% (Net Income TTM 2.89b / Revenue TTM 20.07b)
Gross Margin = 69.01% ((Revenue TTM 20.07b - Cost of Revenue TTM 6.22b) / Revenue TTM)
Gross Margin QoQ = 74.50% (prev 69.93%)
Tobins Q-Ratio = 2.81 (Enterprise Value 122.75b / Total Assets 43.67b)
Interest Expense / Debt = 0.72% (Interest Expense 90.0m / Debt 12.42b)
Taxrate = 4.43% (31.0m / 700.0m)
NOPAT = 2.82b (EBIT 2.95b * (1 - 4.43%))
Current Ratio = 1.62 (Total Current Assets 8.79b / Total Current Liabilities 5.44b)
Debt / Equity = 0.51 (Debt 12.42b / totalStockholderEquity, last quarter 24.23b)
Debt / EBITDA = 2.11 (Net Debt 10.37b / EBITDA 4.91b)
Debt / FCF = 2.86 (Net Debt 10.37b / FCF TTM 3.62b)
Total Stockholder Equity = 23.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.96% (Net Income 2.89b / Total Assets 43.67b)
RoE = 12.53% (Net Income TTM 2.89b / Total Stockholder Equity 23.06b)
RoCE = 8.62% (EBIT 2.95b / Capital Employed (Equity 23.06b + L.T.Debt 11.14b))
RoIC = 8.28% (NOPAT 2.82b / Invested Capital 34.05b)
WACC = 8.26% (E(112.29b)/V(124.71b) * Re(9.10%) + D(12.42b)/V(124.71b) * Rd(0.72%) * (1-Tc(0.04)))
Discount Rate = 9.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.64%
[DCF Debug] Terminal Value 80.41% ; FCFF base≈3.15b ; Y1≈3.89b ; Y5≈6.62b
Fair Price DCF = 64.60 (EV 106.18b - Net Debt 10.37b = Equity 95.81b / Shares 1.48b; r=8.26% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 98.51 | EPS CAGR: 21.12% | SUE: 1.19 | # QB: 12
Revenue Correlation: 98.82 | Revenue CAGR: 16.04% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.79 | Chg30d=-0.002 | Revisions Net=-1 | Analysts=25
EPS current Year (2026-12-31): EPS=3.46 | Chg30d=-0.008 | Revisions Net=-4 | Growth EPS=+13.2% | Growth Revenue=+11.0%
EPS next Year (2027-12-31): EPS=3.92 | Chg30d=-0.020 | Revisions Net=-3 | Growth EPS=+13.1% | Growth Revenue=+10.4%